Vimta Labs Ltd. — Investor Relations & Filings
Vimta Labs Ltd. is a contract research and testing organization providing comprehensive scientific services across multiple sectors. The company specializes in analytical testing, clinical research, preclinical studies, and environmental monitoring. Its service portfolio includes pharmaceutical analysis, biopharmaceutical characterization, food safety testing, and diagnostic services. Vimta operates advanced laboratory facilities equipped to handle complex regulatory requirements, including compliance with global standards such as GLP, GCP, and ISO. The organization supports the life sciences, food, and electronics industries by offering specialized services like molecular biology, microbiology, and toxicology assessments. By integrating multi-disciplinary expertise, the company facilitates product development, quality control, and safety evaluations for a global clientele.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Copy of Newspaper Publication | 2026-05-07 | English | |
| Analysts/Institutional Investor Meet/Con. Call Updates | 2026-05-06 | English | |
| Change in Director(s) | 2026-05-06 | English | |
| Record Date | 2026-05-06 | English | |
| Outcome of Board Meeting | 2026-05-06 | English | |
| Dividend | 2026-05-06 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 42965355 | Copy of Newspaper Publication | 2026-05-07 | English | ||
| 42163555 | Analysts/Institutional Investor Meet/Con. Call Updates | 2026-05-06 | English | ||
| 42166181 | Change in Director(s) | 2026-05-06 | English | ||
| 42171177 | Record Date | 2026-05-06 | English | ||
| 42171303 | Outcome of Board Meeting | 2026-05-06 | English | ||
| 42171271 | Dividend | 2026-05-06 | English | ||
| 42172778 | Press Release | 2026-05-06 | English | ||
| 42173852 | Investor Presentation | 2026-05-06 | English | ||
| 42174392 | Outcome of Board Meeting | 2026-05-06 | English | ||
| 42186784 | Analysts/Institutional Investor Meet/Con. Call Updates | 2026-04-29 | English | ||
| 42275161 | Board Meeting — Financial Results/Dividend | 2026-04-29 | English | ||
| 42275145 | Board Meeting — Board Meeting Intimation | 2026-04-29 | English | ||
| 42200408 | Copy of Newspaper Publication | 2026-04-28 | English | ||
| 42181696 | Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-04-08 | English | ||
| 42188955 | Trading Window | 2026-03-31 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
IMMUPHARMA PLC
Specialty biopharmaceutical company developing peptide-base…
|
IMM | GB | Professional, scientific and te… |
|
IMMUTEP LIMITED
Develops LAG-3 targeting immunotherapies for cancer and aut…
|
IMM | AU | Professional, scientific and te… |
|
IMMUTEP Ltd
Biotechnology company developing LAG-3 immunotherapies for …
|
IMMP | US | Professional, scientific and te… |
|
IMPACT BIOMEDICAL INC.
Develops biopharmaceutical products and technologies to pro…
|
IBO | US | Professional, scientific and te… |
|
IMUGENE LIMITED
Clinical-stage immuno-oncology company developing cancer im…
|
IMU | AU | Professional, scientific and te… |
|
IMV Inc.
Pioneering novel immunotherapies using the proprietary DPX®…
|
IMV | CA | Professional, scientific and te… |
|
INBIOGEN CO.,Ltd
A life sciences firm offering bioinformatics and data minin…
|
101140 | KR | Professional, scientific and te… |
|
Incannex Healthcare Inc.
A clinical-stage biopharma firm developing cannabinoid and …
|
IXHL | US | Professional, scientific and te… |
|
Indaptus Therapeutics, Inc.
Develops bacterial-based immunotherapies for cancer and vir…
|
INDP | US | Professional, scientific and te… |
|
InflaRx N.V.
Clinical-stage biopharmaceutical firm developing C5a/C5aR p…
|
IFRX | NL | Professional, scientific and te… |
Vimta Labs Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/61730/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=61730 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=61730 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=61730 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 61730}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Vimta Labs Ltd. (id: 61730)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.